Zevra Therapeutics, Inc.

DB:1GDA Stock Report

Market Cap: €409.0m

Zevra Therapeutics Past Earnings Performance

Past criteria checks 0/6

Zevra Therapeutics's earnings have been declining at an average annual rate of -18.6%, while the Pharmaceuticals industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 6.9% per year.

Key information

-18.6%

Earnings growth rate

53.3%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate6.9%
Return on equity-128.5%
Net Margin-366.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zevra Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:1GDA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2424-905444
30 Jun 2424-674446
31 Mar 2428-493843
31 Dec 2327-463539
30 Sep 2317-202534
30 Jun 2317-172327
31 Mar 239-382025
31 Dec 2210-271619
30 Sep 2211-351316
30 Jun 2210-301112
31 Mar 2220-171010
31 Dec 2129-63910
30 Sep 2128-65910
30 Jun 2128-6699
31 Mar 2123-5588
31 Dec 2013-1388
30 Sep 2012-1478
30 Jun 2022-81010
31 Mar 2015-181112
31 Dec 1913-251119
30 Sep 1911-241323
30 Jun 190-421232
31 Mar 190-431338
31 Dec 180-561341
30 Sep 180-621341
30 Jun 180-571333
31 Mar 180-531328
31 Dec 170-431320
30 Sep 170-431323
30 Jun 170-451321
31 Mar 170-301421
31 Dec 160-171420
30 Sep 160-161417
30 Jun 160-131317
31 Mar 160-521215
31 Dec 150-55914
30 Sep 150-57815
30 Jun 150-55714
31 Mar 150-29513
31 Dec 140-24512

Quality Earnings: 1GDA is currently unprofitable.

Growing Profit Margin: 1GDA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1GDA is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare 1GDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1GDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: 1GDA has a negative Return on Equity (-128.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/26 07:39
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zevra Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dewey SteadmanCanaccord Genuity
Sumant Satchidanand KulkarniCanaccord Genuity
Louise ChenCantor Fitzgerald & Co.